Cambridge, Mass., USA - September 16, 2009, Cambridge, Mass., USA - AVEO Pharmaceuticals, Inc., a biopharmaceutical company, announced that it has appointed William J. Slichenmyer as chief medical officer and added Robert C. Young to its Board of Directors.
Article continues below
Dr. Slichenmyer received his B.A. and M.D. from Case Western Reserve University. He received postgraduate training in pathology and internal medicine, followed by subspecialty training in medical oncology at the Johns Hopkins Oncology Center, where he also earned a master's degree in clinical investigation.
Dr. Slichenmyer's pharmaceutical industry career spans 15 years in both large and small biopharmaceutical companies where he has contributed to the development of anticancer agents of many classes including cytotoxic drugs, monoclonal antibodies, oligonucleotide therapeutics and targeted small molecules. Prior to joining AVEO, Dr. Slichenmyer most recently served as chief medical officer at Merrimack Pharmaceuticals, where he led the development of novel protein-based therapeutics for patients with cancer and autoimmune diseases.
Before his tenure at Merrimack, Dr. Slichenmyer spent seven years at Pfizer in roles that included global head of oncology clinical development, where he led the development and FDA approval process of the Sutent program, as well as positions in medical affairs and regulatory affairs. Prior to joining Pfizer, Dr. Slichenmyer held various senior level positions at Parke-Davis Pharmaceuticals, Hybridon Inc., Bristol-Myers Squibb Pharmaceutical Research Institute and Burroughs-Wellcome.
Dr. Young received his B.Sc. in zoology from Ohio State University and his M.D. from Cornell University Medical College. He is board-certified in internal medicine, hematology and oncology by the American Board of Internal Medicine. He is president of RCY Medicine, a consulting service focused on cancer center productivity, health care quality and health policy.
Dr. Young previously served as chancellor of Fox Chase Cancer Center in Philadelphia for two years and for 18 years prior to that was its president and chief executive officer. Dr. Young is internationally known for his work in the treatment of lymphoma and ovarian cancer. He is a past-president of the American Society of Clinical Oncology (ASCO), the American Cancer Society and the International Gynecologic Cancer Society. A medical oncologist, Dr. Young is the author of more than 400 peer-reviewed publications. Dr. Young served for seven years as chairman of the Board of Scientific Advisors of the National Cancer Institute.
He is a former member of the National Cancer Policy Board at the Institute of Medicine and is past chairman of the board of the National Comprehensive Cancer Network. A fellow of the American College of Physicians, Dr. Young is also a member of the prestigious American Society of Clinical Investigation. ■